Form 4: Surgery Partners Executive Harrison R. Bane Receives Stock Awards

Harrison R. Bane, National Group President at Surgery Partners, Inc., reports the acquisition of restricted stock awards on March 4, 2025.

Summary

• On March 4, 2025, Harrison R. Bane, National Group President of Surgery Partners, Inc., acquired 17,226 shares of common stock at a price of $23.80 per share through restricted stock awards (RSAs).
• Additionally, Mr. Bane acquired 6,302 shares of common stock at $23.80 per share, also through RSAs.
• Following these transactions, Mr. Bane directly owns 130,565 shares of Surgery Partners, Inc.
• The RSAs granted on March 4, 2025, vest in three equal annual installments beginning on the first anniversary of the grant date, while other RSAs vest on the first anniversary of the grant date.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock awards is a common practice and aligns executive interests with shareholders. There are no explicit negative indicators.

Positives

• The acquisition of restricted stock awards by a company executive can be seen as a positive sign, aligning the executive's interests with those of the shareholders.
• The vesting schedule of the RSAs encourages long-term commitment from the executive.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule of the RSAs suggests a multi-year commitment from the executive.

Industry Context

In the healthcare industry, stock-based compensation is a common practice to attract and retain key executives. The vesting schedules are designed to align executive incentives with long-term company performance.

Comparison to Industry Standards

• Stock awards are a common form of compensation for executives in publicly traded companies, including those in the healthcare sector like Surgery Partners.
• Companies such as HCA Healthcare and Tenet Healthcare also utilize stock awards as part of their executive compensation packages.
• The vesting schedules, typically ranging from one to three years, are consistent with industry norms.

Stakeholder Impact

• Shareholders may view the stock awards positively as they align executive interests with company performance.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

Surgery Partners, Harrison R. Bane, restricted stock awards, SGRY, Form 4, insider trading